Physician Focus on Parkinson's
Issue 15 (Fall 2010) - Quarterly CME Newsletter on Parkinson's Disease
To receive CME credit for this activity, please complete the post-test and evaluation below. Once submitted, a certificate will be issued within two weeks to the email address provided.
CLICK HERE to view Issue 15 online. You may also view the Patient Education Tool online here.
If you have any questions, please contact intellyst® Medical Education at 720-748-8800.
Target Audience
Neurologists, NPs and PAs specializing in neurology.
Statement of Need
Parkinson’s disease (PD) is the second most common neurodegenerative disease. The mean age of onset is 61 years, but may begin as early as age 40 or less. It affects an estimated half million to one million Americans. That number is expected to double in the next 25 years as the population ages and as treatments for other diseases prolong the survival of aging adults. PD is classified as a movement disorder, because its most prominent symptoms are tremor, rigidity, slowed movements, and postural instability. However, PD also includes a wide range of non-motor symptoms, including depression, anxiety, sleep disorder, and autonomic symptoms, and these may be at least as debilitating as motor symptoms for many patients.
Learning Objectives
At the conclusion of this activity, participants should be able to:
• Discuss non-motor features of Parkinson’s disease and their impact on quality of life, including, anxiety, depression, cognitive changes, sensory symptoms, and sleep disorders
• Describe medications available for treatment of motor symptoms of Parkinson’s disease in early and fluctuating disease as well as their side effects
• Summarize the unique nature of the delayed-start clinical trial design and its value in testing potential disease modifying agents in Parkinson’s disease
Disclosures
Andrew Siderowf, MD (Case Study Contributor)
Gary VanderArk, MD (Independent Reviewer)
Richard Robinson (Medical Writer)
Accreditation Statement
intellyst® Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
intellyst® Medical Education designates this activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
|
|
|
|
|
| Which of these statements best illustrates the relationship between REM behavior disorder (RBD) and Parkinsons disease? |
|
| A study of French farm workers showed that: |
|
| According to results from Goldman et al., which of these statements best illustrates the potential relationship between the alpha-synuclein polymorphisms G1 and G2, head trauma, and the risk of PD? |
|
| According to results from Ritz et al., a lower risk of PD is associated with: |
|
| A patient you are seeing for an unrelated condition mentions he has not been able to smell for several years, which you know to be a risk factor for Parkinsons disease. What other aspects of the patients history, if present, would raise your suspicion that the patient may be on the road to developing PD? |
|
| In the ADAGIO study, early-start treatment with ______ met the three pre-specified endpoints, but early-start treatment with ______ did not. |
|
| A post-hoc analysis in the ADAGIO trial suggested that: |
|
| A long-time patient solicits your opinion about the value of combining acupuncture and biofeedback for her PD symptoms, based on reading she has done on the web. What should you reply? |
|
| In the case study, the patient opted to begin treatment with an MAO-B inhibitor based on: |
|
Please indicate your level of agreement with the following statement, with "1" indicating reject completely, and "5" indicating accept completely:
|
| The weight of evidence from the ADAGIO study supports a disease-modifying effect from early treatment at 1 mg per day. | |
|
|
|
|
Please evaluate the activity objectives by selecting how well each has been met, with 5 indicating excellent and 1 indicating poor.
|
| Discuss non-motor features of Parkinsons disease and their impact on quality of life, including anxiety, depression, cognitive changes, sensory symptoms, and sleep disorders | |
| Describe medications available for treatment of motor symptoms of Parkinsons disease in early and fluctuating disease as well as their side effects | |
| Summarize the unique nature of the delayed-start clinical trial design and its value in testing potential disease-modifying agents in Parkinsons disease | |
Please evaluate the effectiveness of the case study by Dr. Andrew Siderowf, in both areas listed below, with 5 indicating excellent and 1 indicating poor.
|
| Usefulness of information presented. | |
| Objectivity/fair balance of content. | |
| Do you intend to make changes or apply this information to your practice as a result of this activity? |
|
Please explain your response to the above question:
|
Was there any commercial bias perceived in relation to this activity? If yes, please describe.
|
Is there anything you would like to communicate to the authors?
|
Suggest topics you would like to see in future activities.
|
| First Name | |
| Last Name | |
| Degree/Credentials | |
| Phone | |
| Fax | |
| Email | |
By typing your name below, this will act as your signature.
|
| Signature | |
| Date | 
|
|
|
|
|
|